Standout Papers

Role of AMP-activated pro... 2001 2026 2009 2017 2001 2019 2016 2002 2011 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Role of AMP-activated protein kinase in mechanism of metformin action
    2001 4.5k citations Gaochao Zhou, Robert P. Myers et al. Journal of Clinical Investigation profile →
  2. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
    2019 820 citations Jamie N. Justice, Anoop M. Nambiar et al. EBioMedicine profile →
  3. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
    2016 730 citations Kenneth Cusi, Beverly Orsak et al. Annals of Internal Medicine profile →
  4. Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes
    2002 670 citations Nicolas Musi, Michael F. Hirshman et al. Diabetes profile →
  5. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
    2011 525 citations Ralph A. DeFronzo, Devjit Tripathy et al. New England Journal of Medicine profile →
  6. Tau protein aggregation is associated with cellular senescence in the brain
    2018 408 citations Nicolas Musi, Joseph M. Valentine et al. Aging Cell profile →
  7. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
    2023 143 citations Mitzi M. Gonzales, Valentina R. Garbarino et al. Nature Medicine profile →
  8. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
    2023 133 citations Anoop M. Nambiar, Dean L. Kellogg et al. EBioMedicine profile →

Immediate Impact

6 by Nobel laureates 32 from Science/Nature 203 hit
Sub-graph 1 of 13

Citing Papers

From geroscience to precision geromedicine: Understanding and managing aging
2025 Hit
Diagnosis and Management of Prediabetes
2023 Hit
26 intermediate papers

Works of Nicolas Musi being referenced

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW
2016
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
2011 Hit
and 18 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Nicolas Musi 8.7k 5.1k 4.0k 3.6k 3.3k 149 15.5k
Mary‐Elizabeth Patti 6.7k 0.8× 5.8k 1.1× 3.0k 0.7× 3.5k 1.0× 2.3k 0.7× 166 14.1k
Varman T. Samuel 7.2k 0.8× 6.2k 1.2× 4.8k 1.2× 3.3k 0.9× 6.2k 1.9× 103 16.5k
Marc Foretz 12.9k 1.5× 5.2k 1.0× 3.7k 0.9× 5.9k 1.6× 3.5k 1.1× 185 20.0k
Daisuke Koya 6.6k 0.8× 3.5k 0.7× 4.0k 1.0× 2.4k 0.7× 3.4k 1.0× 291 18.8k
Guenther Boden 4.7k 0.5× 6.3k 1.2× 4.0k 1.0× 2.9k 0.8× 4.1k 1.2× 164 14.9k
Yasuo Terauchi 7.8k 0.9× 3.9k 0.8× 5.4k 1.3× 4.4k 1.2× 4.3k 1.3× 378 17.3k
Kazuyuki Tobe 9.9k 1.1× 4.8k 1.0× 3.3k 0.8× 3.4k 0.9× 3.7k 1.1× 307 18.5k
Scott A. Summers 9.0k 1.0× 4.9k 1.0× 1.8k 0.4× 2.1k 0.6× 3.5k 1.1× 123 14.4k
Luciano Rossetti 7.7k 0.9× 10.3k 2.0× 4.7k 1.2× 5.6k 1.6× 5.9k 1.8× 154 22.9k
Michael J. Jurczak 5.7k 0.7× 3.6k 0.7× 2.2k 0.5× 1.7k 0.5× 3.4k 1.0× 127 10.7k

All Works

Loading papers...

Rankless by CCL
2026